Jacobs Levy Equity Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Jacobs Levy Equity Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-27,600	Closed	-$155K	–	1164
2016 Q2	$155K	Sell	27,600 -600	-2%	-$3.83K	﹤0.01%	1051
2016 Q1	$152K	Buy	+28,200	New	+$164K	﹤0.01%	1004

Other funds holding SRNE

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jacobs Levy Equity Management's SRNE Position: Q3 2016 in Review

Jacobs Levy Equity Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2016, closing a stake of 27,600 shares — an estimated $155K sold.

Jacobs Levy Equity Management first reported a position in SRNE in Q1 2016 and held it in 2 quarters. The position peaked at $155K in Q2 2016. 62 funds tracked by Wall St. Rank hold SRNE as of Q3 2016.

Jacobs Levy Equity Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Jacobs Levy Equity Management sold 27,600 Sorrento Therapeutics, Inc. shares in Q3 2016, an estimated $155K.
Jacobs Levy Equity Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
Jacobs Levy Equity Management's Sorrento Therapeutics, Inc. position peaked at $155K in Q2 2016.
62 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2016, filed 14 Nov 2016.